CMS plans to place biosimilars and their reference biopharmaceuticals in separate Part B billing codes, and in Part D, plans would have to get CMS approval before replacing biopharmaceuticals with biosimilar versions, according to documents CMS issued Monday (March 30). FDA on March 6 approved the first biosimilar , and CMS released three memos Monday that deal with paying for biosimilars in Part B, Part D and Medicaid , but CMS has a lot of work yet to do on...